OBJECTIVE: To add to data on adverse birth outcomes accounting for disease activity in women with psoriatic arthritis (PsA) and ankylosing spondylitis (AS). METHODS: Data were analyzed from women enrolled in the Organization of Teratology Information Specialists Autoimmune Disease Project from 2004 to 2018. Disease activity was measured according to the Health Assessment Questionnaire (HAQ) or Routine Assessment of Patient Index Data 3 (RAPID3) scores. Poisson regression was used to estimate adjusted risk ratios (ARRs) with 95% confidence intervals (95% CIs) for selected adverse pregnancy outcomes. RESULTS: Compared to healthy controls (n = 717), women with PsA (n = 117) were at increased risk for moderate preterm delivery (32-36 weeks' gestation) (ARR 1.81, 95% CI 1.01-3.26), oligohydramnios (ARR 3.79, 95% CI 1.34-10.74), and cesarean delivery (ARR 1.63, 95% CI 1.26-2.12). Women with AS (n = 129) had an increased risk of delivering infants requiring intensive care (ARR 1.67, 95% CI 1.05-2.67). A high HAQ score at 32 weeks was associated with preterm delivery in women with PsA (ARR 3.82, 95% CI 1.51-9.67). In women with AS, a high RAPID3 score was associated with cesarean delivery (ARR 5.82, 95% 1.06-31.78), and second trimester glucocorticoid use was associated with preterm delivery (ARR 4.41, 95% CI 1.57-12.41). CONCLUSION: Women with PsA and AS have increased risk for selected adverse pregnancy outcomes. Active disease and use of glucocorticoids may increase the risk for some adverse pregnancy outcomes in women with these conditions.
OBJECTIVE: To add to data on adverse birth outcomes accounting for disease activity in women with psoriatic arthritis (PsA) and ankylosing spondylitis (AS). METHODS: Data were analyzed from women enrolled in the Organization of Teratology Information Specialists Autoimmune Disease Project from 2004 to 2018. Disease activity was measured according to the Health Assessment Questionnaire (HAQ) or Routine Assessment of Patient Index Data 3 (RAPID3) scores. Poisson regression was used to estimate adjusted risk ratios (ARRs) with 95% confidence intervals (95% CIs) for selected adverse pregnancy outcomes. RESULTS: Compared to healthy controls (n = 717), women with PsA (n = 117) were at increased risk for moderate preterm delivery (32-36 weeks' gestation) (ARR 1.81, 95% CI 1.01-3.26), oligohydramnios (ARR 3.79, 95% CI 1.34-10.74), and cesarean delivery (ARR 1.63, 95% CI 1.26-2.12). Women with AS (n = 129) had an increased risk of delivering infants requiring intensive care (ARR 1.67, 95% CI 1.05-2.67). A high HAQ score at 32 weeks was associated with preterm delivery in women with PsA (ARR 3.82, 95% CI 1.51-9.67). In women with AS, a high RAPID3 score was associated with cesarean delivery (ARR 5.82, 95% 1.06-31.78), and second trimester glucocorticoid use was associated with preterm delivery (ARR 4.41, 95% CI 1.57-12.41). CONCLUSION:Women with PsA and AS have increased risk for selected adverse pregnancy outcomes. Active disease and use of glucocorticoids may increase the risk for some adverse pregnancy outcomes in women with these conditions.
Authors: Marianne Wallenius; Johan F Skomsvoll; Lorentz M Irgens; Kjell Å Salvesen; Bjorn Y Nordvåg; Wenche Koldingsnes; Knut Mikkelsen; Cecilie Kaufmann; Tore K Kvien Journal: Arthritis Rheum Date: 2011-06
Authors: Suneet P Chauhan; James A Scardo; Edward Hayes; Alfred Z Abuhamad; Vincenzo Berghella Journal: Am J Obstet Gynecol Date: 2010-08-21 Impact factor: 8.661
Authors: Balambal Bharti; Susan J Lee; Suzanne P Lindsay; Deborah L Wingard; Kenneth L Jones; Hector Lemus; Christina D Chambers Journal: J Rheumatol Date: 2015-04-15 Impact factor: 4.666
Authors: Mark Berman; Devy Zisman; Jonathan Wollman; David Levartovsky; Eli Rimon; Ori Elkayam; Daphna Paran Journal: J Rheumatol Date: 2018-09-15 Impact factor: 4.666
Authors: Chelsey J F Smith; Frauke Förger; Gretchen Bandoli; Christina D Chambers Journal: Arthritis Care Res (Hoboken) Date: 2019-07-04 Impact factor: 4.794
Authors: Michael M Ward; Atul Deodhar; Elie A Akl; Andrew Lui; Joerg Ermann; Lianne S Gensler; Judith A Smith; David Borenstein; Jayme Hiratzka; Pamela F Weiss; Robert D Inman; Vikas Majithia; Nigil Haroon; Walter P Maksymowych; Janet Joyce; Bruce M Clark; Robert A Colbert; Mark P Figgie; David S Hallegua; Pamela E Prete; James T Rosenbaum; Judith A Stebulis; Filip van den Bosch; David T Y Yu; Amy S Miller; John D Reveille; Liron Caplan Journal: Arthritis Rheumatol Date: 2015-09-24 Impact factor: 10.995
Authors: Stephanie van den Brandt; Astrid Zbinden; Dominique Baeten; Peter M Villiger; Monika Østensen; Frauke Förger Journal: Arthritis Res Ther Date: 2017-03-20 Impact factor: 5.156